Lipidated IL-22 Alone or Combined with Immunomodulatory Agents Improves Disease Endpoints and Promotes Mucosal Healing in a Mouse Model of Chronic Dextran Sodium Sulfate-Induced Colitis
Transplant surgery
DOI:
10.1007/s10620-025-09007-w
Publication Date:
2025-03-29T08:27:06Z
AUTHORS (8)
ABSTRACT
IL-22 facilitates mucosal healing by directly inducing epithelial regeneration and barrier integrity, which is essential for achieving remission thereby treating inflammatory bowel disease. Here, we evaluated efficacy of a novel lipidated alone in combination with immunomodulatory agents addressing chronic dextran sodium sulfate (DSS)-induced colitis mice demonstrated action on healing. Mice were treated DSS, followed various doses IL-22, anti-TNF antibody, fingolimod, or anti-mouse α4β7 integrin antibody. Additionally, gene expression was determined colonic biopsies from ulcerative patients to assess effects stimulation. Lipidated significantly improved all aspects DSS-induced mice, dose-dependent efficacy. Combinations range showed further additive reductions disease activity, greater than those monotherapies. Immunohistochemistry revealed that increased cell proliferation reduced CD3+ T-cell infiltration, indicating enhanced This supported data after Given the challenges long-term IBD due inflammation damage, presents promising treatment option promotes healing, unlike traditional therapies.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (28)
CITATIONS (0)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....